Market Cap (In USD)
24.48 Million
Revenue (In USD)
709 Thousand
Net Income (In USD)
-21.41 Million
Avg. Volume
4.61 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.771-14.8
- PE
- -
- EPS
- -
- Beta Value
- 0.349
- ISIN
- US54303L1044
- CUSIP
- 54303L104
- CIK
- 1721484
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Joshua Michael Hare FACC, M.D.
- Employee Count
- -
- Website
- https://www.longeveron.com
- Ipo Date
- 2021-02-12
- Details
- Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
More Stocks
-
TRIN
-
ASAHIINDIAAsahi India Glass Limited
ASAHIINDIA
-
NAN
-
300534
-
ST5STEICO SE
ST5
-
SLZNFSlave Lake Zinc Corp.
SLZNF
-
GSFC
-
KFBL